Get started
Author

Madani Rachid

Observed names: Madani RACHID, Madani, Rachid,
OpenAlex ID: A5112263275
GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions
2021 · Sonia Brun, Eloïne Bestion, et al. · Autophagy · 97
PDF
Targeting p53-dependent stem cell loss for intestinal chemoprotection
2018 · Brian J. Leibowitz, Liheng Yang, et al. · Science Translational Medicine · 51
First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers
2022 · James J. Harding, Ahmad Awada, et al. · Liver Cancer · 35
PDF
GNS561 Exhibits Potent Antiviral Activity against SARS-CoV-2 through Autophagy Inhibition
2022 · Eloïne Bestion, Keivan Zandi, et al. · Viruses · 25
PDF
GNS561 acts as a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF-β1 inhibition
2020 · Eloïne Bestion, Zuzana Macek Jilkova, et al. · Therapeutic Advances in Chronic Disease · 18
PDF
Ezurpimtrostat, A Palmitoyl-Protein Thioesterase-1 Inhibitor, Combined with PD-1 Inhibition Provides CD8+ Lymphocyte Repopulation in Hepatocellular Carcinoma
2023 · Eloïne Bestion, Madani Rachid, et al. · Targeted Oncology · 17
Phase I study of veliparib in combination with gemcitabine
2017 · Ronald Stoller, John C. Schmitz, et al. · Cancer Chemotherapy and Pharmacology · 13
LC–MS/MS assay for the simultaneous quantitation of the ATM inhibitor AZ31 and the ATR inhibitor AZD6738 in mouse plasma
2017 · Brian F. Kiesel, Jeffrey C. Shogan, et al. · Journal of Pharmaceutical and Biomedical Analysis · 7
First-in-human phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of oral GNS561, a palmitoyl-protein thioesterase 1 (PPT1) inhibitor, in patients with primary and secondary liver malignancies.
2021 · James J. Harding, Ahmad Awada, et al. · Journal of Clinical Oncology · 6
Population Pharmacokinetics of Gemcitabine and dFdU in Pancreatic Cancer Patients Using an Optimal Design, Sparse Sampling Approach
2017 · Cindy Serdjebi, Florence Gattacceca, et al. · Therapeutic Drug Monitoring · 4
Targeting PPT1 with ezurpimtrostat sensitives liver tumor to immunotherapy by switching cold into hot microenvironments
2023 · Eloïne Bestion, Madani Rachid, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2
PDF
Abstract 899: Remarkable anti-tumor response in a HCC transgenic mouse model treated with GNS561 in combination with anti-PD1
2020 · Madani Rachid, Annemilaï Tijeras-Raballand, et al. · Cancer Research
Gns561 Alone or in Combination With Cisplatin or Gemcitabine for the Treatment of Intrahepatic Cholangiocarcinoma
2019 · Brun, Sonia, Ansaldi, Christelle, et al. · HAL
Gns561, a New Oral Clinical-stage Small Molecule Combined With Anti-pd1 Showed Remarkable Anti-tumor Effects in a Transgenic Immunocompetent Hepatocellular Carcinoma Mouse Model (asv-b)
2019 · Madani, Rachid,, Annemilai, Tijeras-Raballand,, et al. · HAL AMU
Gns561, a New Lysosomotropic Small Molecule, for the Treatment of Liver Fibrosis
2019 · Eloine, Bestion,, Lalmanach, Gilles, et al. · HAL
Abstract 5479: PGx of gemcitabine in pancreatic ADK: Where did we go wrong
2015 · Cindy SERDJEBI, Florence GATTACCECA, et al. · Cancer Research
Works count: 16
Citation count: 275
H-index: 7
I10-index: 7
Year
Topic
Type